Mira Pharmaceuticals Receives Nasdaq Notice for Low Share Price

What Happened
Mira Pharmaceuticals, Inc. (ticker: MIRA) announced on July 31, 2026 that it received a letter from Nasdaq on July 27, 2026 notifying the company it failed to meet the $1.00 minimum closing bid price under Nasdaq Listing Rule 5550(a)(2). Nasdaq’s determination was based on the 30 consecutive business days ended July 24, 2026. The letter does not result in an immediate delisting; Mira has 180 calendar days (until January 25, 2027) to cure the deficiency.

Key Details

• Nasdaq rule cited: Listing Rule 5550(a)(2) (minimum $1 per share bid price).
• Measurement period: 30 consecutive business days ended July 24, 2026; notice dated July 27, 2026.
• Cure period: 180 calendar days (deadline January 25, 2027); regain compliance requires a $1.00 closing bid for at least 10 consecutive business days.
• If eligible, Mira could seek a second 180-day extension (subject to meeting other listing standards) or consider a reverse stock split; if Nasdaq moves to delist, the company may appeal to a Nasdaq Hearings Panel.

Why It Matters
This notice signals a listing compliance risk: if Mira does not meet the $1.00 bid-price requirement within the stated period (or obtain permitted relief), Nasdaq could move to delist the company’s common stock. Delisting or prolonged non-compliance could affect liquidity, investor access, and the stock’s tradability. The company said it will monitor the share price and consider available options to regain compliance but made no assurances it will succeed.